Year in Review: Top Biosimilars-Related Regulatory Developments of 2022

December 31, 2022

Celltrion USA Announces Submission of BLA for Subcutaneous Infliximab Biosimilar 

December 24, 2022

BPCIA Aflibercept Litigation:  Regeneron Files 12(c) Motion to Dismiss Mylan’s Counterclaim for Inequitable Conduct

December 20, 2022

The UK’s MHRA Updates its Guidance on Licensing of Biosimilars

November 17, 2022

Celltrion Files IND with FDA for Adalimumab Biosimilar

August 5, 2022

EMA CHMP Recommends Grant of Marketing Authorization for Three Biosimilars

July 1, 2022

JSR Life Sciences Launches New “Similis Bio” Business Division to Accelerate Biosimilar Development

May 25, 2022

FDA Announces Biosimilar Funding Opportunity

March 17, 2022

China Accepts Innovent Biologics’ Supplemental New Drug Application for Sintilimab Plus Bevacizumab Biosimilar Injection

January 6, 2022

Alvotech’s E.D. Va. Declaratory Judgment Action Against AbbVie Transferred to N.D. Ill.

October 27, 2021